Compare Stocks → Strange new buyer driving up gold (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGENASDAQ:AZRXNASDAQ:MNPRNASDAQ:PPBTNASDAQ:PULM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$3.23$11.07▼$35.71$11.99M1.183,849 shs3,700 shsAZRXAzurRx BioPharma$2.84-2.1%$4.04$3.36▼$26.30$26.49M1.51628,703 shs38,061 shsMNPRMonopar Therapeutics$0.66-2.6%$0.73$0.27▼$1.75$11.52M1.194.50 million shs30,415 shsPPBTPurple Biotech$0.47+0.9%$0.70$0.30▼$2.10$11.74M0.94110,065 shs36,366 shsPULMPulmatrix$1.99+1.5%$1.84$1.55▼$3.14$7.26M0.9218,174 shs11,599 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%-23.61%+4,340.00%+2,916.30%AZRXAzurRx BioPharma-2.07%-16.96%-41.44%-17.92%+10.50%MNPRMonopar Therapeutics+4.31%-11.95%-10.95%+84.99%-47.03%PPBTPurple Biotech+6.15%-25.04%-33.19%-30.61%-77.51%PULMPulmatrix-6.70%-7.14%+20.37%+10.17%-37.10%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics2.7787 of 5 stars3.55.00.00.02.01.70.6PPBTPurple Biotech1.5546 of 5 stars3.54.00.00.01.10.00.6PULMPulmatrix0.9444 of 5 stars3.53.00.00.00.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AMNPRMonopar Therapeutics3.00Buy$2.00202.98% UpsidePPBTPurple Biotech3.00Buy$9.001,835.48% UpsidePULMPulmatrix3.00Buy$10.00402.51% UpsideCurrent Analyst RatingsLatest PPBT, MNPR, AZRX, AGE, and PULM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.003/5/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/27/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00AZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$1.36 per shareN/APULMPulmatrix$7.30M1.00N/AN/A$4.93 per share0.40Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)AZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AMNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)PPBTPurple Biotech-$19.88M-$0.92N/AN/AN/AN/A-57.40%-49.02%5/21/2024 (Estimated)PULMPulmatrix-$14.12M-$3.86N/A∞N/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)Latest PPBT, MNPR, AZRX, AGE, and PULM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 million3/5/2024Q4 2023PPBTPurple Biotech-$0.17-$0.32-$0.15-$0.45N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36AZRXAzurRx BioPharmaN/A1.331.33MNPRMonopar TherapeuticsN/A4.174.17PPBTPurple BiotechN/A2.202.20PULMPulmatrixN/A5.335.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%AZRXAzurRx BioPharma6.27%MNPRMonopar Therapeutics1.83%PPBTPurple Biotech9.64%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%AZRXAzurRx BioPharma7.30%MNPRMonopar Therapeutics41.60%PPBTPurple Biotech2.98%PULMPulmatrix3.61%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionablePPBTPurple Biotech2025.24 million24.49 millionOptionablePULMPulmatrix283.65 million3.52 millionNot OptionablePPBT, MNPR, AZRX, AGE, and PULM HeadlinesSourceHeadlinePulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMCipla Share Pricebusiness-standard.com - March 29 at 7:49 AMPULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMPulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 28 at 11:46 AMPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updateprnewswire.com - March 28 at 9:05 AMCipla Ltd CIPLAmorningstar.com - February 15 at 11:00 PMGlobal deaths from fungal disease have doubled in a decade – new studytheconversation.com - January 13 at 7:42 AMFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersbizjournals.com - January 10 at 7:51 AMPulmatrix shuts down study, explores salebizjournals.com - January 9 at 3:43 PMPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Studynasdaq.com - January 8 at 1:11 PMPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternativesmarketwatch.com - January 8 at 1:11 PMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternativesfinance.yahoo.com - January 8 at 1:11 PMStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steelmsn.com - January 8 at 12:42 AMStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focusmsn.com - January 8 at 12:42 AMTrade Setup for Jan 8: IT earnings to be the Nifty 50's focal point this weekcnbctv18.com - January 7 at 9:11 AMPulmatrix Inc PULMmorningstar.com - November 12 at 9:08 AMPulmatrix Down on Q3 Resultsbaystreet.ca - November 9 at 1:38 PMPulmatrix GAAP EPS of -$1.03, revenue of $1.75Mmsn.com - November 9 at 1:38 PMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 1:38 PMAspergillosis Treatment Research Report 2023finance.yahoo.com - October 23 at 3:27 PMPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100markets.businessinsider.com - September 19 at 9:49 AMPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migrainefinance.yahoo.com - September 19 at 9:49 AMPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowmsn.com - September 11 at 3:15 PMPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazolefinance.yahoo.com - August 23 at 6:11 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come2 Data Storage Device Stocks Thriving From the AI BoomApril 2, 2024 7:25 AMView 2 Data Storage Device Stocks Thriving From the AI BoomMicron Technology Results Proves AI is Driving Storage DemandMarch 26, 2024 7:35 AMView Micron Technology Results Proves AI is Driving Storage DemandYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyAll Headlines Company DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.AzurRx BioPharmaNASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Purple BiotechNASDAQ:PPBTPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.